Melanotan II: what the literature says about risks
MT-II is not FDA-approved and is not currently available through legal compounding channels. This article covers the published risk literature so readers can make sense of what's circulating online.
TL;DR
- Melanotan II (MT-II) is a synthetic melanocortin analog; it is not FDA-approved. FDA removed it from Category 2 in April 2026, and it is not on the 503A bulks list.
- Published case reports and series document serious adverse events including atypical and changing moles, melanocytic lesions, and systemic nausea.
- Gray-market MT-II sourced outside licensed pharmacy channels carries additional risks of contamination, mislabeling, and unknown purity
What it is
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was investigated in early-phase trials for tanning, sexual dysfunction, and appetite suppression. It is structurally related to bremelanotide (PT-141) but is not the same compound — MT-II lacks the same selectivity profile and has a broader melanocortin receptor activity.
The compound is not FDA-approved for any indication. FDA had placed MT-II in Category 2 under its bulk drug substance evaluation process. FDA removed it from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MT-II is not in any FDA 503A category and is not on the 503A bulks list.
How it works
MT-II acts as a non-selective agonist at MC1R, MC3R, MC4R, and MC5R receptors. MC1R activation in melanocytes stimulates melanin production (the tanning effect). MC4R activation affects sexual arousal circuits in the hypothalamus — the same mechanism as bremelanotide, though with less receptor selectivity. MC3R activity has been linked to appetite suppression. The broad receptor profile is part of what makes MT-II's risk profile different from more selective compounds.
Who asks about it
MT-II circulates widely in online fitness and biohacking communities due to its tanning and libido effects. Because it is not available through licensed pharmacy channels, people sourcing it are typically purchasing gray-market products from unregulated suppliers. This article exists to provide factual published-literature context for people who have already encountered MT-II and want independent information about the documented risks.
What the research says
The dermatology literature contains multiple case reports and series documenting melanocytic adverse events in MT-II users. A 2009 case series published in the British Medical Journal documented individuals who developed new or rapidly changing pigmented lesions following MT-II use — findings that prompted urgent dermatological evaluation in each case. A 2011 report in the Journal of the American Academy of Dermatology described atypical nevi and a case of melanoma in an MT-II user with no prior history of melanocytic lesions, with the authors noting that MC1R stimulation is a known pathway in melanocyte proliferation.
Systemic adverse events reported across the literature include significant nausea and vomiting (particularly at higher doses), facial flushing, and spontaneous erections in male users. The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued warnings against MT-II use in 2012 and 2019, citing melanocytic risk, lack of purity data for gray-market products, and the absence of any approved formulation from which dose-safety data could be derived. Australian Therapeutic Goods Administration (TGA) literature similarly documented melanocytic adverse events and listed MT-II as a prohibited import.
What to know before considering it
MT-II is not available from a licensed 503A compounding pharmacy. Products sold as MT-II through online vendors, unregulated research chemical suppliers, or fitness forums are not manufactured under pharmaceutical-grade conditions. Purity, dose accuracy, and sterility cannot be verified. The melanocytic risk documented in peer-reviewed case reports is clinically significant — any individual who has used MT-II and notices new, changing, or unusual pigmented lesions should seek dermatological evaluation promptly.
This article is published to provide accurate information about a compound that is widely discussed but frequently misrepresented.
The Halftime POV
The MT-II literature is a useful illustration of why regulatory classification exists. The compound has biological activity — but the absence of controlled safety data, the melanocytic signal in case reports, and the gray-market supply chain add up to a risk profile that hasn't been adequately characterized for routine clinical use. We think that matters. Being credible means being honest about which compounds have enough supporting evidence and which don't — even when that's not the answer someone was hoping for.
Related reading:
FAQ
Q: What is Melanotan II? A: Melanotan II (MT-II) is a synthetic cyclic peptide analog of alpha-MSH that was developed in the 1980s for tanning research. It acts on melanocortin receptors MC1R (pigmentation), MC3R, and MC4R (sexual arousal, appetite). It is not FDA-approved. FDA removed it from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
Q: What adverse events are documented in the literature? A: Published case reports and literature describe nausea, flushing, spontaneous erections, facial flushing, and melanocytic nevus changes following MT-II use. More serious events documented include exacerbation of existing melanocytic lesions and cardiovascular effects. The case literature largely describes individuals who sourced MT-II from unregulated online vendors — not through licensed clinical channels.
Q: Is Melanotan II available through a compounding pharmacy? A: FDA removed Melanotan II from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. It was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. FDA has said it plans to consult the committee on melanotan II before the end of February 2027.
Disclaimer
FDA removed Melanotan II from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Lim RKW, et al. "Melanotan II and melanocytic lesions." British Medical Journal Case Reports, 2009
- Costagli A, Costagli E. "Melanotan: examining the risks." Journal of the American Academy of Dermatology, 2011
- MHRA Drug Safety Update: Melanotan — Do Not Use, 2012
- Therapeutic Goods Administration (Australia). "Melanotan products: safety concerns." TGA, 2014
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic peptide analog of alpha-MSH that was developed in the 1980s for tanning research. It acts on melanocortin receptors MC1R (pigmentation), MC3R, and MC4R (sexual arousal, appetite). It is not FDA-approved. FDA removed it from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
What adverse events are documented in the literature?
Published case reports and literature describe nausea, flushing, spontaneous erections, facial flushing, and melanocytic nevus changes following MT-II use. More serious events documented include exacerbation of existing melanocytic lesions and cardiovascular effects. The case literature largely describes individuals who sourced MT-II from unregulated online vendors — not through licensed clinical channels.
Is Melanotan II available through a compounding pharmacy?
FDA removed Melanotan II from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. It was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. FDA has said it plans to consult the committee on melanotan II before the end of February 2027.
Keep reading
For better sex, and feeling sure of yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.